SCHEMBL2442471

SCHEMBL2442471

CCC(C)C(=O)Nc1noc2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.52
TP53 P04637 7/20 0.52
MAPT P10636 1/20 0.51
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
KCNJ6 P48051 1/20 0.45
KCNJ3 P48549 1/20 0.45
KDM4E B2RXH2 2/20 0.44
KMT2A Q03164 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
EPHX2 P34913 3/20 0.43
KCNA5 P22460 1/20 0.43
HIF1A Q16665 2/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14427258 0.85 SMN1; SMN2 (0.57) SMN1; SMN2TP53MAPTALOX15TSHR
SCHEMBL2440215 0.82 PRNP (0.41) SMN1; SMN2TP53MAPTKDM4EKMT2A
SCHEMBL2439437 0.82 ALDH1A1 (0.41) SMN1; SMN2TP53MAPTKDM4EKMT2A
SCHEMBL2441818 0.82 ALDH1A1 (0.50) SMN1; SMN2TP53MAPTALOX15TSHR
SCHEMBL2440386 0.82 SMN1; SMN2 (0.44) SMN1; SMN2TP53MAPT
SCHEMBL2441232 0.81 SMN1; SMN2 (0.52) SMN1; SMN2TP53MAPTALOX15TSHR
SCHEMBL2786481 0.80 SMN1; SMN2 (0.51) SMN1; SMN2TP53MAPTALOX15TSHR
SCHEMBL2440986 0.79 SMN1; SMN2 (0.42) SMN1; SMN2TP53ALOX15TSHRKCNJ6
SCHEMBL2440327 0.77 KCNA5 (0.48) SMN1; SMN2TP53MAPTKDM4EKMT2A
SCHEMBL2785768 0.77 SMN1; SMN2 (0.51) SMN1; SMN2TP53MAPTALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893589-B1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS GRUENENTHAL GMBH (DE) 2011-09-14 EP claimed
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof GRUENENTHAL GMBH (DE) 2008-12-18 US claimed
EP-1893589-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2008-03-05 EP claimed
WO-2006131296-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2006-12-14 WO claimed
EP-1893589-B1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS GRUENENTHAL GMBH (DE) 2011-09-14 EP disclosed
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof GRUENENTHAL GMBH (DE) 2008-12-18 US disclosed
EP-1893589-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2008-03-05 EP disclosed
WO-2006131296-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof HTR5A, NPY5R, GRM5 SMN1; SMN2 2423/4885TP53 4882/4885MAPT 1615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.